Literature DB >> 24180375

The high cost of fidelity.

Sarah B Lloyd1, Stephen J Kent, Wendy R Winnall.   

Abstract

The notoriously low fidelity of HIV-1 replication is largely responsible for the virus's rapid mutation rate, facilitating escape from immune or drug control. The error-prone activity of the viral reverse transcriptase (RT) is predicted to be the most influential mechanism for generating mutations. The low fidelity of RT has been successfully exploited by nucleoside and nucleotide analogue reverse transcriptase inhibitors (NRTIs) that halt viral replication upon incorporation. Consequently, drug-resistant strains have arisen in which the viral RT has an increased fidelity of replication, thus reducing analogue incorporation. Higher fidelity, however, impacts on viral fitness. The appearance of compensatory mutations in combination with higher fidelity NRTI resistance mutations and the subsequent reversion of NRTI-resistant mutations upon cessation of antiretroviral treatment lend support to the notion that higher fidelity exacts a fitness cost. Potential mechanisms for reduced viral fitness are a smaller pool of mutant strains available to respond to immune or drug pressure, slower rates of replication, and a limitation to the dNTP tropism of the virus. Unraveling the relationship between replication fidelity and fitness should lead to a greater understanding of the evolution and control of HIV.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24180375      PMCID: PMC3887412          DOI: 10.1089/AID.2013.0153

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  73 in total

1.  Increasing diversity of Human Immunodeficiency Virus type 1 subtypes circulating in Australia.

Authors:  Doris Chibo; Chris Birch
Journal:  AIDS Res Hum Retroviruses       Date:  2012-01-17       Impact factor: 2.205

Review 2.  Biochemical basis of DNA replication fidelity.

Authors:  M F Goodman; S Creighton; L B Bloom; J Petruska
Journal:  Crit Rev Biochem Mol Biol       Date:  1993       Impact factor: 8.250

3.  Molecular architecture of the mutagenic active site of human immunodeficiency virus type 1 reverse transcriptase: roles of the beta 8-alpha E loop in fidelity, processivity, and substrate interactions.

Authors:  K K Weiss; S J Isaacs; N H Tran; E T Adman; B Kim
Journal:  Biochemistry       Date:  2000-09-05       Impact factor: 3.162

4.  Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.

Authors:  Andre J Marozsan; Dawn M Moore; Michael A Lobritz; Erika Fraundorf; Awet Abraha; Jacqueline D Reeves; Eric J Arts
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.

Authors:  Jan Weber; Bikram Chakraborty; Jitka Weberova; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

6.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

Review 7.  Intracellular nucleotide levels and the control of retroviral infections.

Authors:  Sarah M Amie; Erin Noble; Baek Kim
Journal:  Virology       Date:  2012-12-20       Impact factor: 3.616

8.  Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V.

Authors:  Prem L Sharma; James H Nettles; Anya Feldman; Kimberly Rapp; Raymond F Schinazi
Journal:  Antiviral Res       Date:  2009-06-23       Impact factor: 5.970

9.  APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.

Authors:  Andrew E Armitage; Koen Deforche; Chih-Hao Chang; Edmund Wee; Beatrice Kramer; John J Welch; Jan Gerstoft; Lars Fugger; Andrew McMichael; Andrew Rambaut; Astrid K N Iversen
Journal:  PLoS Genet       Date:  2012-03-22       Impact factor: 5.917

Review 10.  HIV-1 Vif, APOBEC, and intrinsic immunity.

Authors:  Ritu Goila-Gaur; Klaus Strebel
Journal:  Retrovirology       Date:  2008-06-24       Impact factor: 4.602

View more
  15 in total

1.  Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells.

Authors:  Joseph A Hollenbaugh; Susan M Schader; Raymond F Schinazi; Baek Kim
Journal:  Virology       Date:  2015-08-29       Impact factor: 3.616

2.  Mutation and recombination frequencies reveal a biological contrast within strains of Cucumber mosaic virus.

Authors:  Justin S Pita; Viktoriya Morris; Marilyn J Roossinck
Journal:  J Virol       Date:  2015-07       Impact factor: 5.103

Review 3.  Decoding HIV resistance: from genotype to therapy.

Authors:  Irene T Weber; Robert W Harrison
Journal:  Future Med Chem       Date:  2017-08-09       Impact factor: 3.808

Review 4.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

Review 5.  Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.

Authors:  Manjunath N Swamy; Haoquan Wu; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2016-03-21       Impact factor: 15.470

6.  Specific amino acids in HIV-1 Vpr are significantly associated with differences in patient neurocognitive status.

Authors:  Will Dampier; Gregory C Antell; Benjamas Aiamkitsumrit; Michael R Nonnemacher; Jeffrey M Jacobson; Vanessa Pirrone; Wen Zhong; Katherine Kercher; Shendra Passic; Jean W Williams; Tony James; Kathryn N Devlin; Tania Giovannetti; David J Libon; Zsofia Szep; Garth D Ehrlich; Brian Wigdahl; Fred C Krebs
Journal:  J Neurovirol       Date:  2016-07-11       Impact factor: 2.643

Review 7.  Quasispecies and virus.

Authors:  Esteban Domingo; Celia Perales
Journal:  Eur Biophys J       Date:  2018-02-03       Impact factor: 1.733

8.  Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.

Authors:  Anna Schneider; Angela Corona; Imke Spöring; Mareike Jordan; Bernd Buchholz; Elias Maccioni; Roberto Di Santo; Jochen Bodem; Enzo Tramontano; Birgitta M Wöhrl
Journal:  Nucleic Acids Res       Date:  2016-02-04       Impact factor: 16.971

Review 9.  The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics.

Authors:  Robert Cox; Richard K Plemper
Journal:  Front Microbiol       Date:  2015-05-12       Impact factor: 5.640

Review 10.  HIV Protease: Historical Perspective and Current Research.

Authors:  Irene T Weber; Yuan-Fang Wang; Robert W Harrison
Journal:  Viruses       Date:  2021-05-06       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.